Keyphrases
Antiviral Activity
100%
Remdesivir
100%
SARS-CoV-2 Variants
100%
GS-441524
100%
COVID-19
66%
IC50 Value
50%
Nsp12
33%
Variant of Interest
33%
SARS-CoV-2 Variants of Concern
33%
Virus
16%
Nucleoprotein
16%
RNA-dependent RNA Polymerase (RdRP)
16%
FDA-approved Drugs
16%
Publicly Available
16%
Disease Severity
16%
Viral Transmission
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Prodrug
16%
Genetic Variation
16%
Vaccine Effectiveness
16%
Nucleoside Analogues
16%
Activity Measurement
16%
Neutralizing Antibodies
16%
Nucleosides
16%
Effective Concentration
16%
Antiviral Treatment
16%
Recombinant Virus
16%
Plaque Reduction Assay
16%
Disease Transmission
16%
Continued Use
16%
Vaccine Antibodies
16%
Rapid Spread
16%
Delta Variant
16%
Multiple Variants
16%
Omicron Variant
16%
P323L
16%
SARS-CoV-2 Antivirals
16%
Medicine and Dentistry
Antiviral Activity
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Remdesivir
100%
Omicron Coronavirus Variant
100%
COVID-19
28%
Virus Transmission
14%
Enzyme Linked Immunosorbent Assay
14%
Disease Severity
14%
Nucleoprotein
14%
Antiviral Therapy
14%
Neutralizing Antibody
14%
Nucleoside
14%
RNA Directed RNA Polymerase
14%
Genetic Variation
14%
Virus Recombinant
14%
Prodrug
14%
Virus
14%
Nucleoside Analog
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antiviral Activity
100%
SARS Coronavirus
100%
Remdesivir
100%
EC50
57%
Enzyme-Linked Immunosorbent Assay
14%
Antivirus Agent
14%
Prodrug
14%
Virus Transmission
14%
Neutralizing Antibody
14%
RNA Directed RNA Polymerase
14%
Disease Severity
14%
Nucleoprotein
14%
Nucleoside
14%
Nucleoside Analog
14%